Fortrea's Q4 and Annual Performance Review
Fortrea Holdings Inc. (NASDAQ: FTRE) recently shared its financial results for the fourth quarter and the full year of 2024, demonstrating a resilient growth trajectory driven by focused operational strategies.
Fourth Quarter Highlights
During the fourth quarter, Fortrea reported revenues of $697.0 million, reflecting a slight decrease from $709.7 million in Q4 of the previous year. The company faced a GAAP net loss of $73.9 million, equating to a diluted loss per share of $0.82, compared to a net loss of $48.6 million and a loss per share of $0.55 the prior year.
Financial Metrics
Despite the challenges, adjusted EBITDA for this quarter stood at $56.0 million, down from $58.9 million in the year-ago quarter. Fortrea's book-to-bill ratio for Q4 was reported at 1.35x, indicating solid demand for its services.
Full-Year Financial Overview
For the entire year, Fortrea reported total revenues of $2.696 billion, a decrease from $2.842 billion in 2023. The company’s net loss for the year was $271.5 million with a diluted loss per share of $3.03 versus a loss of $31.7 million and $0.36 per share the previous year.
Year-End Metrics and Backlog
For 2024, adjusted EBITDA totaled $202.5 million, down from $245.8 million in 2023. The trailing twelve-month book-to-bill ratio was 1.16x, and as of December 31, 2024, Fortrea's backlog was recorded at an impressive $7.699 billion.
Financial Position
At year-end, Fortrea had cash and cash equivalents of $118.5 million and total gross debt of $1.142 billion. For the same year, the company generated an operating cash flow of $262.8 million, along with a free cash flow of $237.3 million.
Outlook for 2025
As we look to the future, Fortrea is targeting revenues in the range of $2.45 billion to $2.55 billion for the full year of 2025, with an adjusted EBITDA guidance set between $170 million and $200 million. This forecast assumes steady foreign currency exchange rates impacting the financial results.
Engagement with Stakeholders
The company expressed its intent to discuss the 2025 financial guidance during its upcoming earnings call scheduled for 9:00 AM ET. Interested participants are encouraged to prepare in advance to facilitate smooth engagement.
Who is Fortrea?
Fortrea Holdings Inc., is positioned as a leading global provider of clinical development solutions catered to the life sciences industry. The firm collaborates with both emerging and established biopharmaceutical, biotechnology, medical device, and diagnostic companies to expedite healthcare innovations that deliver transformative therapies to patients. Fortrea’s impressive capabilities encompass phase I-IV clinical trial management, clinical pharmacology, and consulting services.
Global Presence
With three decades of rich experience across over 20 therapeutic areas, Fortrea's dedicated workforce operates in nearly 100 countries, ensuring that it can provide tailored and agile solutions to its diverse customer base.
Frequently Asked Questions
1. What were Fortrea's total revenues for Q4 2024?
Fortrea reported Q4 revenues of $697.0 million.
2. How does Fortrea's performance in Q4 2024 compare to Q4 2023?
The company experienced a decrease in revenues compared to Q4 2023, which totaled $709.7 million.
3. What is the expected revenue range for Fortrea in 2025?
Fortrea targets revenues between $2.45 billion and $2.55 billion for the full year 2025.
4. What was Fortrea's book-to-bill ratio for Q4 2024?
The book-to-bill ratio for Q4 2024 was 1.35x.
5. What services does Fortrea offer?
Fortrea provides clinical trial management, clinical pharmacology, and consulting services for the life sciences sector.
